AustralianSuper Pty Ltd acquired a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,512 shares of the medical research company’s stock, valued at approximately $1,017,000.
Other institutional investors also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter worth about $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter worth about $27,000. Activest Wealth Management raised its position in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the period. Physician Wealth Advisors Inc. raised its position in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the period. Finally, Westside Investment Management Inc. raised its position in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Institutional investors own 89.62% of the company’s stock.
Wall Street Analysts Forecast Growth
IQV has been the topic of several research reports. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. UBS Group dropped their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, March 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Finally, Royal Bank Of Canada started coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $225.69.
IQVIA Stock Performance
Shares of IQV opened at $169.56 on Friday. The stock’s 50-day simple moving average is $170.14 and its 200 day simple moving average is $199.19. The stock has a market capitalization of $28.30 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 1.63 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More
- Five stocks we like better than IQVIA
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
